<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893307</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0825</org_study_id>
    <secondary_id>NCI-2013-01879</secondary_id>
    <secondary_id>2012-0825</secondary_id>
    <secondary_id>R03CA188162</secondary_id>
    <secondary_id>R56DE025248</secondary_id>
    <secondary_id>U19CA021239</secondary_id>
    <nct_id>NCT01893307</nct_id>
  </id_info>
  <brief_title>Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer</brief_title>
  <official_title>Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II/III trial studies the side effects and how well intensity-modulated&#xD;
      proton beam therapy works and compares it to intensity-modulated photon therapy in treating&#xD;
      patients with stage III-IVB oropharyngeal cancer. Radiation therapy uses high-energy x-rays,&#xD;
      protons, and other types of radiation to kill tumor cells and shrink tumors. It is not yet&#xD;
      known whether intensity-modulated proton beam therapy is more effective than&#xD;
      intensity-modulated photon therapy in treating oropharyngeal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the rates and severity of late grade 3-5 toxicity between intensity-modulated&#xD;
      photon therapy (IMRT) and intensity-modulated proton therapy (IMPT) following the treatment&#xD;
      of oropharyngeal tumors. (Phase II) II. To compare the rate of 3-year progression-free&#xD;
      survival (PFS) between concurrent chemo-radiation strategies with IMRT and IMPT following the&#xD;
      treatment of oropharyngeal tumors. (Phase III)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Disease-related outcomes (2-year progression-free survival, patterns of failure, 2-year&#xD;
      overall survival, 2-year [yr] distant metastasis free survival, and second primary cancers).&#xD;
      (Phase III) II. Patient Reported Outcome (PRO) measures of symptoms using MD Anderson Symptom&#xD;
      Inventory (MDASI), MD Anderson Dysphagia Inventory (MDADI), Functional Assessment of Cancer&#xD;
      Therapy-Head and Neck (FACT-HN), Xerostomia and Health Questionnaire (European Quality of&#xD;
      Life 5-Dimension three level scale [EQ-5D-3L]), work status (Work Productivity and Activity&#xD;
      Impairment: Specific Health Problem [WPAI: SHP]). (Phase III) III. Physician reported&#xD;
      toxicity using Common Terminology Criteria for Adverse Events (CTCAE)-4.0. (Phase III) IV.&#xD;
      Quality-Adjusted-Life-Years (QALY) comparison between IMPT and IMRT. (Phase III) V.&#xD;
      Cost-benefit economic analysis of treatment. (Phase III) VI. To determine whether specific&#xD;
      molecular profiles are associated with overall or progression-free survival. (Phase III) VII.&#xD;
      To investigate associations between changes in serum biomarkers or human papillomavirus&#xD;
      (HPV)-specific cellular immune responses measured at baseline and three months with overall&#xD;
      or progression-free survival. (Phase III) VIII. To bank peripheral blood at time of&#xD;
      enrollment, weeks 2, 4, and 6 during treatment and during follow up visits for 2 years to&#xD;
      explore the ability of circulating markers to predict outcome. (Phase III) IX. To bank head&#xD;
      and neck tissues to explore the ability of tissue-based markers to predict outcome. (Phase&#xD;
      III) X. To bank peripheral blood and tissues for future interrogations. (Phase III) XI. Acute&#xD;
      side effects of radiation therapy will be assessed. (Phase III)&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To assess potential differences between patients on study and patients who were considered&#xD;
      eligible for randomized, were randomized to a treatment arm, but were denied insurance&#xD;
      coverage for the treatment arm she/he was randomized to; or may have dropped out of the study&#xD;
      for other reasons after being randomized. These patients will compromise Group 3: consisting&#xD;
      of patients randomized to Protons but not treated and Group 4: consisting of patients&#xD;
      randomized to IMRT but not treated at the designated institution. Furthermore, these patients&#xD;
      will only be followed for recurrence and survival.(Phase III)&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients undergo IMRT once daily (QD) five days a week for approximately 6.5 weeks.&#xD;
&#xD;
      ARM II: Patients undergo IMPT QD five days a week for approximately 6.5 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 1 year,&#xD;
      every 4 months for 1 year, and then every 6 months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2013</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of late onset grade 3+ toxicity anytime (Phase II)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The methods described by Gooley will be used to estimate the cumulative incidence of late onset grade 3+ toxicity by 2 years for each treatment arm with death as a competing risk. The methods of Fine and Gray will be used to model the cumulative incidence of late onset grade 3+ toxicity by 2 years as a function of treatment arm and other potential prognostic factors (e.g., human papillomavirus (HPV)/p16 status, use of induction chemotherapy) considering death as a competing risk. Hazard ratios for the prognostic factors from this model with 95% confidence intervals will be estimated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of acute grade 3+ toxicity (Phase II)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be graded according to the NCI CTCAE version 4.0. The methods described by Gooley will be used to estimate the cumulative incidence of late onset grade 3+ toxicity by 2 years for each treatment arm with death as a competing risk. The methods of Fine and Gray will be used to model the cumulative incidence of late onset grade 3+ toxicity by 2 years as a function of treatment arm and other potential prognostic factors (e.g., HPV/p16 status, use of induction chemotherapy) considering death as a competing risk. Hazard ratios for the prognostic factors from this model with 95% confidence intervals will be estimated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS) (Phase II)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Stratified by treatment arm and estimated using the product limit estimator of Kaplan and Meier. Cox proportional hazards regression will be used to model OS as a function of potential prognostic factors. Hazard ratios for the prognostic factors from this model will be estimated with 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Phase III)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be summarized at critical time points using the method of Kaplan-Meier. Kaplan-Meier plots will be used to visualize the time-to-event information by treatment arm, and the trial will be monitored based on results from log-rank tests used to compare treatment arms. Furthermore, Cox proportional hazards regression will be used to assess the time-to-event outcomes while adjusting for covariates of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (Phase III)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be summarized at critical time points using the method of Kaplan-Meier. Kaplan-Meier plots will be used to visualize the time-to-event information by treatment arm, and the trial will be monitored based on results from log-rank tests used to compare treatment arms. Furthermore, Cox proportional hazards regression will be used to assess the time-to-event outcomes while adjusting for covariates of interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) (Phase II and III)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>QoL assessments will be summarized using the mean score and standard deviation for each time point of interest. Mean response trajectories will be plotted over the time horizon for each QoL instrument administered to patients in order to explore differences between treatment arms along with other patient characteristics of interest. Other analyses such as area under the curve and linear mixed models will be used to make statistical comparisons between treatment arms while adjusting for covariates of interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">518</enrollment>
  <condition>Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <condition>Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm I (IMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo IMRT QD five days a week for approximately 6.5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (IMPT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo IMPT QD five days a week for approximately 6.5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm I (IMRT)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
    <other_name>Radiation, Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMPT</description>
    <arm_group_label>Arm II (IMPT)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
    <other_name>Radiation, Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (IMRT)</arm_group_label>
    <arm_group_label>Arm II (IMPT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon Beam Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm I (IMRT)</arm_group_label>
    <other_name>Photon EBRT</other_name>
    <other_name>Photon External Beam Radiotherapy</other_name>
    <other_name>Radiation, Photon Beam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Beam Radiation Therapy</intervention_name>
    <description>Undergo IMPT</description>
    <arm_group_label>Arm II (IMPT)</arm_group_label>
    <other_name>PBRT</other_name>
    <other_name>Proton</other_name>
    <other_name>Proton EBRT</other_name>
    <other_name>Proton External Beam Radiotherapy</other_name>
    <other_name>Proton Radiation Therapy</other_name>
    <other_name>Radiation, Proton Beam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (IMRT)</arm_group_label>
    <arm_group_label>Arm II (IMPT)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented squamous cell carcinoma of the oropharynx (American Joint&#xD;
             Committee on Cancer [AJCC] version [v]7 stage III-IV A,B)&#xD;
&#xD;
          -  Tumor tissue (primary or cervical metastasis) available for human papilloma virus&#xD;
             (HPV) and/or p16 (in situ hybridization [ISH], immunohistochemistry [IHC] or&#xD;
             genotyping testing); if you do not have enough leftover tumor tissue available, you&#xD;
             will have a tumor biopsy for tumor marker testing&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status = 0, 1, or 2&#xD;
&#xD;
          -  Negative pregnancy test for women of child bearing potential&#xD;
&#xD;
          -  Concurrent chemotherapy&#xD;
&#xD;
          -  Bilateral neck radiation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiation treatment for head and neck mucosal primary cancers within the past&#xD;
             5 years (i.e. oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity)&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Clinically significant uncontrolled major cardiac, respiratory, renal, hepatic,&#xD;
             gastrointestinal or hematologic disease but not limited to:&#xD;
&#xD;
               -  Symptomatic congestive heart failure, unstable angina, or cardiac dysrhythmia not&#xD;
                  controlled by pacer device&#xD;
&#xD;
               -  Myocardial infarction within 3 months of registration&#xD;
&#xD;
          -  Distant metastases (stage IV C, any T, any N and M1)&#xD;
&#xD;
          -  Previous surgical resection or neck dissection for oropharyngeal cancer, administered&#xD;
             with therapeutic intent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Frank</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Snider, MD</last_name>
      <email>jwsnider@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>James Snider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir H. Patel</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Samir H. Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roi Dagan</last_name>
      <email>rdagan@floridaproton.org</email>
    </contact>
    <investigator>
      <last_name>Roi Dagan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noah Kalman, MD</last_name>
      <email>NoahK@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Noah Kalman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark W. McDonald</last_name>
      <email>mark.mcdonald@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Mark W. McDonald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Cancer Center Warrenville</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasiruddin Mohammed</last_name>
      <email>nasiruddin.Mohammed@nm.org</email>
    </contact>
    <investigator>
      <last_name>Nasiruddin Mohammed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willis-Knighton Medical and Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanford R. Katz</last_name>
      <phone>318-212-8671</phone>
      <email>sanfordkatzmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sanford R. Katz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Molitoris</last_name>
      <email>jmolitoris@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Molitoris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul M. Busse</last_name>
      <phone>877-726-5130</phone>
      <email>pbusse@partners.org</email>
    </contact>
    <investigator>
      <last_name>Paul M. Busse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Hyde</last_name>
      <phone>810-342-4200</phone>
      <email>Christian.Hyde@mclaren.org</email>
    </contact>
    <investigator>
      <last_name>Christian Hyde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Foote</last_name>
      <phone>855-776-0015</phone>
      <email>foote.robert@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Robert L. Foote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Proton Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Y. Lee</last_name>
      <phone>212-639-3341</phone>
      <email>Leen2@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Y. Lee</last_name>
      <email>leen2@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Y. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Henson</last_name>
      <email>christina-henson@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Christina Henson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Lin</last_name>
      <phone>412-647-8073</phone>
      <email>alexander.lin@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in The Woodlands</name>
      <address>
        <city>Conroe</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Frank</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Steven J. Frank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Frank</last_name>
      <phone>713-563-2300</phone>
      <email>sjfrank@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Steven J. Frank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson West Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Frank</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Steven J. Frank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson League City</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Frank</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Steven J. Frank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson in Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Frank</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Steven J. Frank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gopal Bajaj, MD</last_name>
      <email>gopal.bajaj@inova.org</email>
    </contact>
    <investigator>
      <last_name>Gopal Bajaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Upendra Parvathaneni</last_name>
      <phone>206-616-8289</phone>
      <email>upendra@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Upendra Parvathaneni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

